Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim vs rhTPO for chemotherapy-induced thrombocytopenia in non-myeloid malignancies
ChiCTR2500113618Phase 3Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in chemotherapy-induced thrombocytopenia (CIT) comparing romiplostim group with rhTPO group (2 arms). Primary endpoints: vital signs, clinical physical examination and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
romiplostimrecombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2500113618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113618.